One of the major hurdles people with hemophilia face is complying with their medication schedule — in particular, injecting themselves several times a week with clotting factor.
Clotting factor has a relatively short half-life (the time it takes for a person’s clotting factor levels to drop to 50 percent, which can range from eight to 36 hours). The shorter the half-life, the more often patients will need to administer the factor.
Extended half-life (EHL) treatments allow hemophilia patients to go longer between clotting factor infusions. More extended half-life products are now available for people living with the condition. These products allow patients to have better treatment adherence, need fewer weekly injections, and improved clinical outcomes. Find out more about extended half-life products here.
Hemophilia News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.